Neoplasms

Blood and Lymph Conditions

All Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Myeloid

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Philadelphia Chromosome

Lymphoma

Neoplasms by Histologic Type

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Myeloproliferative Disorders

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Translocation, Genetic

Chromosome Aberrations

Myeloid Leukemia

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Chronic Graft Versus Host Disease

Chronic Myeloid Leukemia

Acute Graft Versus Host Disease

Lymphosarcoma

Chronic Myeloproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Dasatinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.

Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour.

MK0457

Oral dasatinib 70 mg b.i.d. tablets twice daily.

dasatinib

Medical Monitor

This study will evaluate MK0457 in combination with Dasatinib in patients with Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Efficacy and Safety will be evaluated.

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

A Phase I Dose Escalation of MK0457 in Combination With Dasatinib in Patients With Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Merck Sharp & Dohme LLC

Syndrome

Preleukemia

Myelodysplastic Syndromes

Anemia

Leukemia, B-Cell

Anemia, Refractory

Blast Crisis

Precancerous Conditions

Cell Transformation, Neoplastic

Carcinogenesis

Neoplastic Processes

Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration

In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.

MK0457 in Patients With Leukemia (0457-003)

A Phase I/II Dose Escalation Study of MK0457 in Patients With Leukemia

Respiratory Tract (Lung and Bronchial) Diseases

Carcinoma, Non-Small-Cell Lung

Carcinoma

Lung Neoplasms

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days

This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

A Phase IIA Study Evaluating the Efficacy of MK0457 as a 5-Day Continuous Infusion in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days

This study will evaluate MK0457 in patients with chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be evaluated.

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

A Phase II Study of MK0457 in Patients With T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)	NCT00500006	Chronic Myeloge... Leukemia, Lymph...	MK0457 dasatinib	18 Years -	Merck Sharp & Dohme LLC
MK0457 in Patients With Leukemia (0457-003)	NCT00111683	Chronic Myeloge... Lymphocytic Leu... Myelodysplastic... Myelogenous Leu...	MK0457	18 Years -	Merck Sharp & Dohme LLC
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)	NCT00290550	Carcinoma, Non-...	MK0457	18 Years -	Merck Sharp & Dohme LLC
MK0457 in Patients With Leukemia (0457-003)	NCT00111683	Chronic Myeloge... Lymphocytic Leu... Myelodysplastic... Myelogenous Leu...	MK0457	18 Years -	Merck Sharp & Dohme LLC
A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)	NCT00405054	Leukemia	MK0457	18 Years -	Merck Sharp & Dohme LLC
A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)	NCT00500006	Chronic Myeloge... Leukemia, Lymph...	MK0457 dasatinib	18 Years -	Merck Sharp & Dohme LLC
A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)	NCT00290550	Carcinoma, Non-...	MK0457	18 Years -	Merck Sharp & Dohme LLC

Spots Global Cancer Trial Database for mk0457

Every month we try and update this database with for mk0457 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mk0457

Every month we try and update this database with for mk0457 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mk0457 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.